louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06927700: Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes
Official title: Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tobacco Product Beliefs and Use
Keywords: smokeless tobacco
tobacco advertising
modified risk claims
snus
moist snuff
Lead sponsor: Rutgers, The State University of New Jersey
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2025-04-15
Enrollment: 1257
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will be an online survey experiment conducted with adults who smoke cigarettes (ages 21+) to examine their reactions to modified risk advertising claims authorized by the Food \& Drug Administration (FDA) for two smokeless tobacco brands (General Snus and Copenhagen), which describe the lower risks of these products compared to cigarette smoking. The study will compare effects of ads with different two different claim types (i.e. claims about reduced lung cancer risk and claims about reduced risks for multiple disease) versus ads with no reduced-risk claims, and examine effects on message and product perceptions, and interest in using the smokeless tobacco products. This study will also examine how smokers' reactions/interest may vary based on the product brand, and asses prior awareness/exposure to the authorized claims.


Eligibility criteria: Inclusion Criteria:

* Adults (age 21 and over) who are current established cigarettes smokers (i.e., smoked 100 cigarettes in their lifetime and now smoke every day or somedays), based in the US, members of Ipsos' KnowledgePanel, and have chosen to complete their research panel surveys in English

Exclusion Criteria:

* Panel participants who do not meet the criteria outlined above will be excluded.

Primary outcomes:
measure: Product Relative Harm/Risk Perceptions
timeFrame: Assessed in survey measures completed immediately after viewing the study stimuli
measure: Product Use Intentions
timeFrame: Assessed in survey measures completed immediately after viewing the study stimuli
Secondary outcomes:
measure: Message Recall
timeFrame: Assessed in survey measures completed immediately after viewing the study stimuli
measure: Add and message perceptions
timeFrame: Assessed in survey measures completed immediately after viewing the study stimuli
measure: Switching comprehension
timeFrame: Assessed in survey measures completed immediately after viewing the study stimuli
measure: Main cause of smoking harms
timeFrame: Assessed in survey measures completed immediately after viewing the study stimuli
Other outcomes:
Locations:
city: New Brunswick
country: United States
facility: Rutgers Institute for Nicotine & Tobacco Studies
state: New Jersey
Study officials:
affiliation: Rutgers University
name: Olivia A Wackowski, PhD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05959200: Clinical Performance Evaluation of Two Frequent Replacement Silicone Hydrogel Toric Contact Lenses
Official title: Clinical Performance Evaluation of Two Frequent Replacement Silicone Hydrogel Toric Contact Lenses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ametropia
Myopia
Hyperopia
Astigmatism
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2023-07-25
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The primary objective of this study is to evaluate the axis orientation of LID226397 toric contact lenses.

Detailed description: Subjects will be expected to attend 7 visits including a screening visit. The total duration of a subject's participation in the study will be approximately 40 days.

Eligibility criteria: Key Inclusion Criteria:

* Successful wearers of any commercial soft toric contact lenses (except AOfAHP and daily disposable lenses) in both eyes with at least 3 months wearing experience, with a minimum wearing time of 5 days per week and 10 hours per day.
* Able to be fit with and wear contact lenses within the available range of sphere \& cylinder power and axes.
* Best corrected distance visual acuity greater than or equal to 20/25 Snellen (0.10 logMAR) in each eye as determined by manifest refraction at screening.
* Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

* Wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment.
* Habitual AOfAHP contact lens wearers and habitual daily disposable lens wearers (worn within last 3 months).
* Other exclusion criteria may apply.

Primary outcomes:
measure: Percentage of Lenses With Axis Orientation Within Plus or Minus 30 Degrees From the Intended Axis at 10 Minutes After Lens Insertion
timeFrame: Day 1 Dispense, 10 minutes after lens insertion, for each wear period. Each wear period is approximately 14 days according to randomization assignment.
Secondary outcomes:
Other outcomes:
Locations:
city: Oakland
country: United States
facility: Dr. Elsa Pao, OD
state: California
city: San Francisco
country: United States
facility: Pacific Rims Optometry
state: California
city: Maitland
country: United States
facility: Drs. Giedd, P.A.
state: Florida
city: Orlando
country: United States
facility: Vision Health Institute
state: Florida
city: Franklin Park
country: United States
facility: Franklin Park Eye Center, PC
state: Illinois
city: Granville
country: United States
facility: ProCare Vision Centers, Inc.
state: Ohio
city: Memphis
country: United States
facility: Optometry Group, PLLC
state: Tennessee
Study officials:
affiliation: Alcon Research, LLC
name: Clinical Trial Lead, CRD Vision Care
role: STUDY_DIRECTOR
References:
Clinical trial NCT03077100: Identification of Pathogens in the Neonatal Intensive Care Unit (NICU)
Official title: Identification of Pathogens and Their Antibiogram in the Neonatal Intensive Care Unit (NICU)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pathogen Resistance
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2017-03-10
Enrollment: 2000
Sex: ALL
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Newborns hospitalized in NICU with positive cultures

Brief summary: To aim of this study is to identify the pathogens and their distribution in the NICU and to determine whether empirical antibiotics are suitable for the treatment of sepsis in the unit.


Eligibility criteria: Inclusion Criteria:

* Newborns with positive cultures

Exclusion Criteria:

-

Primary outcomes:
measure: Antibiogram
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
affiliation: Hillel Yaffe Medical Center
name: Michael Feldman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01181700: A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers
Official title: An Open Study To Estimate The Plasma Pharmacokinetics Of PF-00241939 Administered Via Oral Inhalation Using Dry Powder Inhalers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pharmacokinetics
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2010-08-13
Enrollment: 42
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to investigate the time course of PF-00241939 concentrations in the blood following dosing by oral inhalation using dry powder inhalers.


Eligibility criteria: Inclusion Criteria:

* Healthy male and/or female subjects between the ages of 21 and 55 years.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
* Pregnant or nursing females.
* A positive urine drug screen.

Primary outcomes:
measure: Plasma pharmacokinetic parameters: AUClast and Cmax.
timeFrame: 36 hours
Secondary outcomes:
measure: Plasma pharmacokinetic parameters: AUC24, AUCinf, Tmax and half-life.
timeFrame: 36 hours
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06303700: Dyspnea, Risk of Falling and Quality of Life in Adolescents, Youth and Geriatric Groups
Official title: Dyspnea, Risk of Falling and Quality of Life in Adolescents, Youth and Geriatric Groups
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Public Health
Lead sponsor: Delta University for Science and Technology
Sponsor class: OTHER
First posted: 2024-03-12
Enrollment: 604
Sex: ALL
Minimum age (years): 12
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: All subjects were recruited from inhabitants of urban and rural areas in the Nile Delta Region, Egypt. They were assigned into 3 age-difference groups (adolescents, youth, and geriatrics).

Brief summary: To assess the correlation between aspects of the dyspnea scale (indicating poor functionality), the fall efficacy scale (indicating a higher fear of falling), and all aspects of the SF36 (indicating quality of life) in 3 age groups: adolescents, youth, and geriatrics.

Detailed description: An observational study was done to assess the correlation between aspects of the dyspnea scale (indicating poor functionality), the fall efficacy scale (indicating a higher fear of falling), and all aspects of the SF36 (indicating quality of life) in 3 age groups: adolescents, youth, and geriatrics. The participants in each group were assessed using the previously mentioned scales. Then the relationships between them were calculated and analyzed.

Eligibility criteria: Inclusion Criteria:

The participants were male or female community-dwellers, They ranged in age: adolescents from 12 to 17 years old, youth from 20 to 22 years old, and geriatrics from 60 to 80 years old.

Exclusion Criteria:

subjects with mobility disabilities and severe cognitive impairments.

Primary outcomes:
measure: the severity of dyspnea
timeFrame: At the baseline evaluation
measure: the level of fear of falling through daily life activities
timeFrame: At the baseline evaluation
measure: quality of life and public health
timeFrame: At the baseline evaluation
Secondary outcomes:
Other outcomes:
Locations:
city: Gamasa
country: Egypt
facility: Amira Hussin Mohammed
Study officials:
References:
Clinical trial NCT03218852: Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
Official title: An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: IgA Nephropathy
Lead sponsor: Guangdong Provincial People's Hospital
Sponsor class: OTHER
First posted: 2017-07-17
Enrollment: 133
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is an extended follow-up of the study (ClinicalTrials.gov ID: NCT01758120)-Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone alone in patients with advanced-stage IgA nephropathy.


Eligibility criteria: Inclusion Criteria:

* biopsy-proven primary IgA nephropathy
* 18-70 years old
* elevated serum Creatinine and less than 3.0mg/dl
* with a written consent from participants to receive prednisone and/or cyclophosphamide

Exclusion Criteria:

* diabetes;
* contraindications for the treatment of prednisone and/or cyclophosphamide
* any treatment with steroids or immunosuppressive drugs prior to this study
* acute deterioration of renal function(including those of glomerular origin)

Primary outcomes:
measure: the changes of kidney function or death
timeFrame: a total of 5 years of followup (addition of 2-year-follow up to the ClinicalTrial of NCT01758120)
Secondary outcomes:
measure: the changes of proteinuria
timeFrame: a total of 5 years of followup (addition of 2-year-follow up to the ClinicalTrial of NCT01758120)
measure: Number of Participants with Adverse Events
timeFrame: a total of 5 years of followup (addition of 2-year-follow up to the ClinicalTrial of NCT01758120)
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangdong General Hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT06496152: Knowledge, Attitude, and Perceptions Towards Artificial Intelligence Among Dental Students
Official title: Knowledge, Attitude, and Perceptions Towards Artificial Intelligence Among Dental Students of Faculty of Dentistry, Tanta University, Egypt
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Artificial Intelligence
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2024-07-11
Enrollment: 371
Sex: ALL
Minimum age (years): 18
Maximum age (years): 24
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A cross-sectional study will be adopted using an online-based questionnaire that will be sent to dental students in the Faculty of Dentistry, Tanta University. The link of the survey will be created using Microsoft form and will be disseminated through various open social media groups of dental students

Brief summary: The aim of this study will be to assess knowledge, attitudes, and perceptions towards Artificial intelligence among dental students of Faculty of Dentistry, Tanta University

Detailed description: A cross-sectional study will be adopted using an online-based questionnaire that will be sent to dental students in the Faculty of Dentistry, Tanta University. A questionnaire will be adopted from an existing similar pre validated study. The link of the survey will be created using Microsoft form and will be disseminated through various open social media groups of dental students.

Eligibility criteria: Inclusion Criteria:

* all dental students of Faculty of Dentistry, Tanta University

Exclusion Criteria:

* The postgraduate students

Primary outcomes:
measure: The online form by questionnaire
timeFrame: Two months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Aldowah O, Almakrami A, Alghuwaynim Y, Alhutaylah M, Almansour A, Alswedan A, Alshahrani F, Alqarni S, Alkasi Y. Perceptions and Knowledge of Undergraduate Dental Students about Artificial Intelligence in Dental Schools: A Cross-sectional Study. J Contemp Dent Pract. 2024 Feb 1;25(2):148-155. doi: 10.5005/jp-journals-10024-3633.
Clinical trial NCT00132652: Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B
Official title: A Randomized Trial of Switching Antiviral Therapy From Lamivudine to Telbivudine (LdT) vs. Continued Lamivudine Treatment in Adults With Chronic Hepatitis B
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Hepatitis B
Lead sponsor: Novartis
Sponsor class: INDUSTRY
Collaborators: name: Novartis Pharmaceuticals
First posted: 2005-08-22
Enrollment: 240
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is being conducted to compare the safety and effectiveness of switching treatment from lamivudine to telbivudine (LdT) against continued lamivudine treatment. Results from patients who were taking lamivudine and then switched to telbivudine will be compared with the results from patients who continued on lamivudine alone.


Eligibility criteria: Inclusion Criteria:

* Documented clinical history compatible with chronic hepatitis B
* Patient has compensated liver disease
* Patient has received previous treatment with lamivudine for a duration of at least 3 months and not more than 12 months

Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Patient is pregnant or breastfeeding
* Patient is co-infected with hepatitis C, hepatitis D or HIV
* Patient previously received antiviral treatment for hepatitis B other than lamivudine in the preceding 12 months

Other protocol-defined exclusion criteria may apply.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
state: California
city: New York
country: United States
state: New York
city: Philadelphia
country: United States
state: Pennsylvania
city: Westmead
country: Australia
city: Toronto
country: Canada
state: Ontario
city: Montreal
country: Canada
state: Quebec
city: Beijing
country: China
city: Nice
country: France
city: Tel Aviv
country: Israel
city: Auckland
country: New Zealand
city: Singapore
country: Singapore
city: Tainan
country: Taiwan
city: Chiang Mai
country: Thailand
city: London
country: United Kingdom
Study officials:
References:
Clinical trial NCT04947852: Efficacy of NIV Masks in COPD
Official title: Efficacy of NIV Masks in COPD Patients With Chronic Respiratory Failure: A Randomized Controlled Cross Over Pilot
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COPD
Lead sponsor: Fisher and Paykel Healthcare
Sponsor class: INDUSTRY
First posted: 2021-07-01
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: A randomized controlled pilot study to compare the efficacy and tolerability of a two different NIV masks on carbon dioxide in participants with stable chronic obstructive pulmonary disease (COPD) with chronic type II respiratory failure.


Eligibility criteria: Inclusion Criteria:

* A doctor's diagnosis of COPD
* PtCO2 ≥45mmHg on transcutaneous monitor at baseline measure
* Oxygen saturation measured by pulse oximetry (SpO2) ≥85%
* Fits the study mask
* Can tolerate the therapy

Exclusion Criteria:

* FEV1/FVC ≥70%
* Body mass index \>35
* Hypercapnia considered to be primarily due to Obesity Hypoventilation syndrome and/or Obstructive Sleep Apnea
* Any condition which makes NIV contra-indicated as per BTS guidelines based on clinical judgement

Primary outcomes:
measure: Transcutaneous Carbon Dioxide
timeFrame: 60 minutes
Secondary outcomes:
measure: Oxygen Saturation
timeFrame: 60 minutes
measure: Minute Ventilation
timeFrame: 60 minutes
measure: Heart Rate
timeFrame: 60 minutes
measure: Respiratory Rate
timeFrame: 60 minutes
measure: Borg Dyspnoea Score
timeFrame: 60 Minutes
Other outcomes:
Locations:
city: Wellington
country: New Zealand
facility: Medical Research Institute New Zealand
Study officials:
affiliation: Medical Research Institute of New Zealand
name: Alex Semprini
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06637852: Sexual and Urinary Function Improvement for Cancer Survivors
Official title: Sexual and Urinary Function Improvement for Cancer Survivors- Promoting Access to Collaborative Treatment (SUFICS-PACT)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Urinary Dysfunction
Sexual Dysfunction
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2024-10-15
Enrollment: 200
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to test the efficacy of SUFICS-PACT to identify and treat sexual and urinary dysfunction in prostate cancer survivors at NYC H+ H/Bellevue, the oldest public hospital in the US. This study will evaluate the implementation of an adapted sexual and urinary function collaborative care model at NYC Health+Hospitals/Bellevue. The study will test the efficacy of this collaborative care model through a randomized controlled trial in the adult primary care clinic; the intervention arm will receive collaborative treatment consisting of a care manager who has specialty training in mental health and psychosexual counseling, a primary care nurse practitioner who leads symptom management, primary care physicians who supervise the team, and a team specialty consult liaison.


Eligibility criteria: Inclusion Criteria:

* At least 18 years old
* Have a diagnosis of prostate cancer
* Have sought care/treatment for prostate cancer

Exclusion Criteria:

* Patients under 18 years old
* Patients who have not sought care/treatment for prostate cancer
* Patients who are categorized as "vulnerable subjects," such as minors or incarcerated individuals.

Primary outcomes:
measure: Number of patients identified and treated for sexual dysfunction
timeFrame: Year 5
measure: Number of patients identified and treated for urinary dysfunction
timeFrame: Year 5
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
affiliation: NYU Langone Health
name: Nnenaya A. Mmonu, MD, MS
role: PRINCIPAL_INVESTIGATOR
References: